CC-115 is a dual inhibitor of DNA-PK and mTOR (targeting both TORC1 and TORC2 complexes), primarily used in cancer research and treatment. It inhibits enzymes involved in cell growth, survival, and DNA repair, key processes often dysregulated in cancers. By blocking the mTOR signaling pathway and DNA-PK-mediated repair, CC-115 suppresses tumor growth, proliferation, and resistance to therapies. It is being studied in clinical trials for solid tumors (e.g., prostate, breast, lung), hematologic malignancies, and lymphomas. Additionally, its mechanism enhances the efficacy of radiation and chemotherapy by impairing DNA repair in cancer cells, making it a promising candidate for overcoming resistance to other mTOR inhibitors.